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D URING the last 2 decades there has been 
a revolution in the understanding of 
hepatic pathophysiology and in the treatment 
of liver disease. Liver transplantation per se 
has been a major factor in this broad move-
ment, particularly as increasing numbers of 
chronic survivors have inched out to, and now 
beyond, the first decade of posttransplanta-
tion life. The dangers of liver transplantation 
are moving into the acceptable range for the 
first time. This year we have performed six 
liver replacements. All six recipients are well. 
Well over 50% of last year's liver recipients 
are well. The ancillary research permitted by 
these patients h~s been fundamental, as for 
example, observations on correction of inborn 
errors of metabolism I. 
However, liver transplantation has in-
fluenced hepatology in such broad and more 
subtle ways that instead of saying more about 
this procedure, its p,ast, or its future, I will 
talk about the fall-out benefits that have been 
coincidental from research and development 
in liver transplantation. An obvious example 
is the perfection of techniques for major 
hepatic resections, such as right trisegmentec-
tomy (extended right hepatic lobectomy). 
Historically, this operation; in which 75%-
90% of hepatic parenchyma is removed, has 
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had an operative mortality averaging almost 
40%. By applying technical and management 
principles from our liver transplantation expe-
rience, the operative mortality has been 
reduced to 3% or lessY 
Such an achievement is of interest mainly 
to surgeons. In contrast, an important area of 
broadly applicable basic research in portal 
physiology has derived from efforts at liver 
transplantation. 
HEPATOTROPHIC FACTORS 
The notion that portal venous blood 
possessed qualities not found in other kinds of 
blood repeatedly surfaced in and receded 
from the literature during the nearly 100 
years before 1965. However, the hypothesis of 
portal blood specificity was not established 
until the early 1960s, when it was found that 
auxiliary liver homografts placed in an 
ectopic location and doubly revascularized 
with arterial plus systemic venous blood 
underwent striking atrophy and other abnor-
malities within a few days.4,5 The small graft 
shown in Fig. 1 had been the same size as the 
native liver at the time of transplantation a 
few weeks earlier. 
Such acute atrophy also was found in 
non transplant models, such as the so-called 
split transposition.6 With this preparation, 
one liver fraction was nourished with splanch-
nic venous blood via a portal branch. It 
remained healthy. The other liver fraction 
supplied with equal volumes of or greater 
systemic venous inflow underwent atrophy 
and tissue damage. 
The hypothetical ingredients in venous 
blood returning from the splanchnic organs 
were termed hepatotrophic factors. But what 
were they? The first solid clues were not 
unearthed until 1972 and 1973. Then, using 
different kinds of split liver techniques in 
dogs, circumstantial evidence was obtained 
that the hepatotrophic factors were endoge-
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Fig. 1. The auxiliary homo-
graft (right) and the recipient 
dog's own liver (left) In an exper-
Iment In which the host and 
transplanted organ8 . had origI-
nally been about the 8ame 8lze. 
P08toperatlve Immun08uppre8-
810n wa8 with azathioprine. Note 
Jhe well pre8erved but dimen-
sionally reduced general 8truc-
ture of the homograft. The gall-
bladder did not 'hrlnk propor-
tionately. The 8peclmens were 
obtained 45 day, after tran8plan-
tatlon. (Reproduced by perml ... 
810n of Annals of Surgery.') 
nous hormones. 7 One particularly useful prep-
aration was splanchnic division in which 
venous return from the pancreas and other 
upper abdominal organs was given to part of 
the liver, whereas the other part was given 
intestinal venous return (Fig. 2). The liver 
region nourished with venous blood from the 
pancreas and duodenum had large, glycogen-
rich, and ultrastructurally healthy hepato-
cytes compared to the atrophic hepatocytes 
nourished with venous return from the intes-
tines. Pancreatectomy or the creation of 
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alloxan diabetes (Fig. 2) eliminated or dimin-
ished the regional differences. 8 
The unmasking of these effects in split liver 
models had a simple explanation. It appeared 
that the splanchnic hepatotrophic substances 
were largely cleared by one passage through 
hepatic tissue. Therefore, hepatotrophic fac-
tors passing through one liver fragment 
became unavailable for the other competing 
fragment, which suffered accordingly. From 
the evidence just cited, endogenous insulin 
seemed to be the most important hepato-
PANCREATECTOMY 
Flg_ 2. Splanchnic dlvl810n 
experlment8. In the8e dOg8, the 
right liver lobe, received venOU8 
return from the pancreatlcoga8-
troduoden08plenlc region, and 
the left liver lobe8 received 
venous blood from the Inte,-
tlne8. In other experlment8 the 
Intestinal blood waa directed 
Into the right lobe, with pan-
creatic now to the left ,Ide. (A) 
Nondiabetic dog'; (8) alloxan-
Induced diabetic dog'; (e) dog, 
with total pancreatectomy. (Re-
produced by perml8slon of Sur-
gery, Gynecology and Obs'e'-
rlcs.·) Splanchnic division 
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trophic factor. However, all of our work 
indicated that other splanchnic factors were 
also important. The nature of these noninsulin 
contributory splanchnic factors, which have 
been assumed to be multiple, has not been 
accurately determined. Other hormones (such 
as glucagon) and nutrients absorbed from the 
intestinal tract have been suggested. 
A crucial experiment to test the hepato-
trophic role of insulin was carried out in 1975, 
using the ECk fistula (complete portacaval 
shunt) model. In all species so far studied, 
including man, complete portal diversion 
causes characteristic hepatic changes, which 
in dogs are essentially complete within 4 
days.9 The changes are identical to those in 
the portaprival liver fragments of split liver 
. experiments that I just described. Canine 
hepatocytes shrink to about half their original 
size within 4 days and become infiltrated with 
fat. Various organelles become abnormal, the 
most specific change being disruption and 
quantitative loss of rough endoplasmic reticu-
lum. There is an increase in thymidine incor-
poration and mitotic activity to about three 
times the previous level.9 
Portacaval 
shunt 
Body 
woll 
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Insulin was tested in such dogs in the 
following way. At the time of Eck fistula, a 
continuous infusion of nonhypoglycemic doses 
of insulin (with or without glucagon) was 
given into the tied off left portal vein (Fig. 3). 
The left lobes could then be compared to the 
pres hunt control tissues as well as to the 
nontreated right lobar tissues, and to the 
findings in control untreated animals after 
Eck fistula. 
The results were clear.9 Insulin prevented 
most of the acute damage caused by Eck 
fistula, but only in the directly infused left 
lobes. Atrophy was largely prevented and so 
were most of the expected light and electron-
microscopic changes. Glucagon, with insulin 
or by itself, had no demonstrable effect. In 
addition to the foregoing effects, insulin treat-
ment in Eck fistula dogs influenced the rate of 
hepatocyte cell renewal. Thymidine incorpo-
ration and actual mitoses were increased 
about four times in the infused lobes but not 
on the other side. 
At long last, the explanation for the 
mysterious Eck fistula syndromes was at 
hand. In essence, these syndromes seemed to 
Pump 
Fluid with 
insulin 
Fig. 3. Experiments In which 
Eck's fistula Is performed and 
postoperative Infusions are 
made into the left portal vein. 
(Reproduced by permission of 
Lancet.") 
------.-----
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be caused largely by the loss to the liver of 
direct exposure to hormones (especially 
insulin), which were being diverted from their 
natural transhepatic route, even though they 
were returned in diluted form through the 
arterial circulation. The secondary complica-
tions of Eck fistula, such as encephalopathy 
and weight loss, were presumably derivative 
from the liver changes. With the liver changes 
came other subtle but profound metabolic 
consequences. For example, there was a fall in 
serum lipid components, such as cholesterol 
and phospholipids,IO which was at least part\y 
due to a reduction in hepatic cholesterol 
synthesis. 
Quite understandably, the morphological 
effects of Eck fistula in dogs can be dupli-
cated by another straightforward procedure, 
namely, removal of all non hepatic splanchnic 
organs. 11 Here also, the structural and ultra-
structural changes could be greatly reduced 
or even prevented by the continuous infusion 
of insulin into the now virtually nonexistent 
portal circulation. I I 
There are broad implications to the concept 
that the liver is more than a way-station for 
splanchnic hormones and that a functional 
interplay exists between the splanchnic 
hormone sources and the liver. Although the 
clearest example is with insulin, the same 
potential exists with polypeptides, nutrients, 
and other substances of splanchnic origin that 
are normally brought to the liver in high 
concentration on first pass. The role of this 
splanchnic-hepatic axis in understanding 
liver physiology and liver disease is a task to 
which we will be addressing ourselves for a 
long time to come. The subject is germane to 
an important question in pancreatic trans-
plantation, namely: Where is the optimal 
place to put pancreatic grafts? 
HEPATIC REGENERATION AND 
HEPATOTROPHIC FACTORS 
The suspicion has been entertained by US7,12 
and by others that the foregoing splanchnic 
factors influence the hepatic regeneration 
that follows liver injury or partial hepatecto-
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my. That hormones such as insulin can affect 
the rate of hepatocyte proliferation has been 
clearly established in many experimental 
models, including the insulin infusion experi-
ments described earlier.9 The work of Bucher 
at Harvardl3 and the San Diego investigators 
directed by Orloffl4 has been particularly 
influential. 
As would be predicted, evisceration 
changes the normal course of regeneration. 15 
If total pancreatectomy is performed at the 
time of or before partial hepatectomy, regen-
eration is delayed and diminished but by no 
means eliminated. Retention of the pancreas 
but removal of all other nonhepatic splanch-
nic organs has a similar or even greater but 
still incomplete inhibiting effect on regenera-
tion. 15 However, when all the non hepatic 
splanchnic organs are excised, regeneration is 
brought to a dead standstill, and it cannot be 
restored to normal with insulin or insulin/ glu-
cagon therapyY 
What is the role of hepatotrophic factors in 
liver regeneration? The hypothesis that 
hormone interactions create an initiating 
climate for regeneration is compatible with 
data on secondary messenger systems ob-
tained in our laboratories l5,16 and elsewhere. 
After liver resection in rats and dogs, early 
rises and later declines in cyclic adenosine 
monophosphate (AMP), adenyl cyclase, hor-
mone binding, and polyamine concentration 
precede regeneration by many hours. These 
orderly changes '6 are perturbed by all of the 
evisceration procedures that inhibit or abolish 
regeneration,15 but it is not known if such 
associations and iatrogenically caused disas-
sociations represent cause or effect. 
INTRAHEPATIC GROWTH CONTROL FACTORS 
About 2 years ago, we concluded that our 
investigations of hepatic growth control 
needed a new direction. We began a search 
for factors within the liver itself that could 
influence liver growth. Although this concept 
had important historical roots going back 20 
years, it has been controversial because of 
conflicting and inconsistent experimental 
results. 
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Our approach was simple. By ultracentrifu-
gation at 140,000 g, we made canine hepatic 
cytosol extracts that were free of cell 
membranes, organelles, and viruses. Such 
cytosol contains proteins and other constitu-
ents that are soluble but no insulin and very 
little glucagon. The cytosol was tested in the 
same Eck fistula model described earlier (Fig. 
3) by injecting it as a 4-6-hr bolus into the 
tied off left portal vein, just after completion 
of the portacaval shunt. 
The results were remarkable. 17 Cytosol 
from normal adult livers had no effect on the 
events that follow Eck fistula, nor did the 
cytosol prepared from liver fragments 
remaining after 72% hepatectomy performed 
I day earlier. However, 2-day regenerating 
liver changed the pattern of results, and 3-day 
regenerating liver was even more potent. In 
the directly infused left liver lobes these latter 
cytosol extracts inititiated a burst of regener-
ation that had a delayed onset (Fig. 4). The 
increased mitoses were not clearly seen until 2 
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Fig. 4. Number 01 thymidine-labeled hepatocytes per 
1000 hepatocytes. Cytosollrom normal and 24-hr regener· 
atlng livers does not alter the pattern that occurs after 
portacaval shunt (no treatment group). The 48-hr and 
particularly the 72-hr regenerating liver cytosol has a 
marked stimulatory effect at 2 and 3 days. (Reproduced by 
permission of Viewpoints on Oigestive Oisease 11: 1-4, 
1979.) 
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days after the pulse of cytosol had been given, 
with a response that was doubled again at 3 
days and almost completely confined to the 
directly treated lobes. 
Proliferation was not the only cytosol 
effect. The atrophy characteristic of Eck 
fistula proceeded for 2 days after the delivery 
of the active liver extracts, but between the 
second and third days, there was a dramatic 
reversal (Fig. 5). Now the hepatocytes 
returned to normal size at the same time as 
other structural and ultrastructural features 
of these liver cells were restored to or toward 
normal. The result at 3 days was a liver in 
which healthy hepatocytes in the left, but not 
the right, liver lobes were undergoing changes 
indistinguishable from vigorous regenera-
tion. 
Such observations create a new dimension 
for research in regeneration. The findings will 
have to be reconciled with the earlier work on 
hepatotrophic factors. The appearance of the 
growth factor in regenerating livers is depen-
dent on portal blood input, since no stimulat-
ing substance can be found in liver fragments 
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Fig. 5. Cytosol from normal and 24-hr regenerating 
livers does not alter the atrophy that occurs after porta-
caval shunt (no treatment group). The 48-hr and particu-
larly the 72-hr regenerating liver cytosol causes reversal of 
these changes between the second and third days. (Repro-
duced by permission of Viewpoints on Oigestlve Olsease 
11:1-4, 1979.) 
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of dogs subjected to concomitant eviscera-
tion. 18 There are other lines of inquiry. Isola-
tion and identification of the growth factor 
should be possible by standard biochemical 
techniques, and it should be tested for species 
and organ specificity. 
CLINICAL IMPLICATIONS 
General Considerations 
Implications of the hepatotrophic concept 
have already been mentioned or implied, 
including: the planning of optimum vasculari-
zation of liver homografts; the possibility of 
the provision of an hepatic renewal stimulus 
in patients with acute hepatic disease who 
exhibit poor regeneration; the better under-
standing of a variety of liver diseases as these 
are influenced or even caused by pertubations 
of the hepatic-splanchnic axis; and a better 
understanding of nonhepatic diseases (dia-
betes mellitus, for example) the courses of 
which are probably effected by interorgan 
relationships. 
In addition, the hepatotrophic concept 
should be part of the consciousness in choos-
ing portal-systemic shunt procedures for 
control of hemorrhage from esophageal 
varices. In principle, the Warren-type proce-
dure should be the best, since it can decom-
press the dangerous gastroesophageal venous 
collaterals with minimum acute loss of resid-
ual hepa topetal flow. 19 
Portal Diversion and Inborn Errors of 
Metabolism 
Glycogen Storage Disease 
Historically, portacaval shunt has been 
used clinically for mechanical objectives-
decompression of the portal venous system 
and relief of ascites. More recently, portal 
diversion has been performed for metabolic 
purposes. The first such application was for 
glycogen storage disease.20-22 We have treated 
10 such patients who now have potential 
follow-ups of 3.5-16 years. Their liver 
enzyme deficiencies were of glucose-6-phos-
phatase (type 1, 6 examples), amylo-1-6-
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glucosidase (type 3, 3 examples), and phos-
phorylase (type 6, 1 example). AlllO children 
had growth retardation, and 9 had recurrent 
hypoglycemia and acidosis. Secondary hyper-
lipidemia, coagulation disorders, hyperuri-
cemia, and bone dysplasia were common. 
After complete portacaval shunt, the 
insulin rise in systemic blood after a glucose 
meal was markedly increased compared to 
preoperatively.21.22 All metabolic abnormali-
ties were immediately ameliorated or fully 
corrected except for nocturnal hypoglycemia. 
All the children had striking growth spurts, at 
an average rate of more than 0.5 cm/month 
for the first year. Later biopsies of the livers 
showed no decrease in the glycogen concen-
tration and no change in the enzymes. 
However, the hepatocytes had undergone the 
kind of atrophy described earlier in animals. 
This, plus the increased total body growth, 
resulted in a relative decrease in the hepato-
megaly, which was a common preoperative 
complaint. Bone growth and maturation were 
striking (Fig. 6). 
The subsequent important investigations of 
Folkman et al. of Harvard23 have shown that 
many of these benefits can be achieved by 
continuous alimentation with glucose or an 
elemental diet delivered through a gastro-
stomy or oral feeding tube. The relative roles 
of portal diversion versus continuous alimen-
tation (singly or together) for the treatment of 
glycogen storage disease will undoubtedly be 
clarified in the next few years. 
Hyperlipidemia 
In a second metabolic disease, namely, 
homozygous type II hyperlipidemia, a reason-
able nonsurgical option is not available. 
Patients with this disorder have serum choles-
terol concentrations of 600-1200 mg/dl. 
They progressively develop xanthomatous 
deposits in numerous external contact areas. 
Such deposits internally in the coronary 
arteries and heart valves inevitably lead to 
lethal cardiovascular complications, usually 
by the teen years. Medical and dietary treat-
ment are ineffective. 
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Fig. 6. The dramatic wrist and hand bone growth and mineralization in the Ilrat 11.5 p08toperatlve montha. The 
bracket on the left index finger ia 5 em in length. (Reproduced by perml8slon 01 Annals of Surgery.") 
In 1973, we performed end-to-side porta-
caval shunt on a patient whose serum choles-
terol concentrations fel1 from about 800 
mg/dl preoperatively to about 350 mg/dl. At 
the time, visible xanthomatous deposits disap-
peared and a moderate aortic stenosis 
regressed. 23-25 Unfortunately, she had suf-
fered a major myocardial infarction a few 
weeks before the portal diversion, leading to a 
myocardial aneurysm . Nineteen months after 
the portal diversion she died suddenly while 
walking from school. The cause of death 
probably was a cardiac arrhythmia . 
We have treated five other patients with 
type II hyperlipidemia. 21 .26 One subsequently 
had an aortic valve replacement and triple 
coronary artery bypass . The two oldest of 
these patients have fol1ow -ups now of 4.5-5.5 
years. All five of the surviving patients have 
had major cholesterol declines as wel1 as 
resorption of xanthomas. Careful metabolic 
studies on one of these patients revealed a 
substantial decline in hepatic cholesterol 
synthesis27 analagous to that observed in 
normal dogs. IO It is likely that decreased 
hepatic lipid synthesis is only one of multiple 
factors accounting for the antilipidemic effect 
of portacaval shunt. In any event, the antilipi-
demic effect of portal diversion has been 
confirmed in many centers throughout the 
world. 
It is interesting that pathologic changes 
caused by portal diversion in the seemingly 
normal human liver are indistinguishable 
from those produced in animals. The changes 
include atrophy, organelle disruption, fatty 
infiltration, and especially loss of rough endo-
plasmic reticulum . Despite this, the human 
(like the rat) has been resistant to encephalo-
pathy and other devastating complications of 
Eck fistula that regularly kil1 dogs, swine, and 
baboons within a few months. 28 
Alpha/-Antitrypsin Deficiency 
It seems likely that there are still some 
spirits left in the Pandora's box I have been 
discussing. Some preliminary observations in 
three patients with alphal-antitrypsin defi-
ciency have suggested that this third inborn 
error of metabolism also can be ameliorated 
by portacaval shunt. These three children 
with deteriorating liver function had porta-
caval anastomosis 4, 2.5, and 0.5 years ago. 
The hepatic disease has not progressed since 
then. One of the patients had a repeat biopsy 
more than a year after the operative proce-
dure. The hepatocyte atrophy and other 
changes of portacaval shunt were found. In 
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addition, intrahepatic granules, which are 
thought to be abnormal alpha I-antitrypsin, 
were quantitated by a morphometric tech-
nique. The intrahepatic granules had de-
crease<! in number. Since these deposits have 
been thought to be the cause of the cirrhosis 
of this disease, a rational explanation is at 
hand for the clinical benefit. Presumably, the 
portacaval shunt diminished the synthesis by 
the liver of the abnormal glycoprotein without 
commensurately reducing its transport out of 
the liver. 
Within a month or two, we will be rebiopsy-
ing a second of these three patients. If the 
aforementioned histopathologic observations 
are confirmed, we will consider expanding 
this clinical trial. Even if portal diversion fails 
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in some cases, it has been established that the 
inborn error can be cured by the drastic final 
step of liver replacement.29 
SUMMARY 
Apart from its own intrinsic importance, 
liver transplantation has been the stimulus for 
development of better techniques of hepatic 
surgery and for a better understanding of 
hepatic physiology. A particularly important 
off-shoot of transplantation has been the 
recognition that factors (called hepato-
trophic) are present in the portal blood. The 
nature of these factors and their influence on 
the liver have been discussed, as well as the 
clinical implications of the hepatotrophic 
concept. 
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